TRIM21 and interstitial lung disease: Anti-Ro52 positivity predicts extraglandular involvement—particularly ILD, vasculitis, and autoimmune overlap syndromes—and frequently co-occurs with anti-Jo-1 or anti-MDA5, reflecting shared interferon pathways across diseases.